Taysha Gene Therapies (TSHA) Common Equity (2019 - 2026)

Taysha Gene Therapies has reported Common Equity for 8 years, with the latest figure at $211.9 million in Q1 2026.

• Quarterly Common Equity rose 284.94% year-over-year to $211.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $211.9 million (up 284.94% YoY) and the FY2025 annual result came in at $246.9 million, up 245.25% from the prior year.
• Common Equity eased to $211.9 million in Q1 2026 per TSHA's latest filing, from $246.9 million in the prior quarter.
• Over five years, Common Equity peaked at $248.7 million in Q2 2025 and troughed at -$49.1 million in Q3 2023.
• A 5-year average of $80.8 million and a median of $55.1 million in 2025 frame the typical range for Common Equity.
• The widest YoY moves for Common Equity: up 7796.42% in 2023, down 558.88% in 2023.
• Over 5 years, Common Equity stood at $949000.0 in 2022, then surged by 7796.42% to $74.9 million in 2023, then decreased by 4.55% to $71.5 million in 2024, then surged by 245.25% to $246.9 million in 2025, then fell by 14.17% to $211.9 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $211.9 million, $246.9 million, and $219.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.